cas 1001-26-9|| where to buy Ethyl 3-ethoxy-2-propenoate

Product Name:Ethyl 3-ethoxy-2-propenoate

IUPAC Name:ethyl (2E)-3-ethoxyprop-2-enoate

Packing Unit	Available Stock	Price($)
CM247241-250g	in stock	ŉǵ
CM247241-500g	in stock	ȃƓů
CM247241-1000g	in stock	ŗĲŗ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:1001-26-9; Molecular Formula:C7H12O3; Melting Point:-; Smiles Code:O=C(OCC)/C=C/OCC; Density:

: Catalog Number:CM247241; Molecular Weight:144.17; Boiling Point:195.5°C at 760 mmHg; MDL No:MFCD00009863; Storage:Store at 2-8°C.

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Repotrectinib; Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.